Shattuck Labs Announces Participation in Upcoming March Conferences

AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two investor conferences in March 2023.

Presentation Details

Conference: Cowen 43rd Annual Health Care Conference
Format: Novel IO Panel Discussion
Presenter: Dr. Lini Pandite, MBChB, M.B.A., Shattuck’s Chief Medical Officer
Date: March 6, 2023
Time: 9:10-10:10 a.m. ET

Conference: Oppenheimer 33rd Annual Healthcare Conference
Format: Corporate Presentation
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: March 13, 2023
Time: 2:00-2:30 p.m. ET

A live webcast of the panel discussion and presentation will be available on the Investors section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
[email protected] 

You May Also Be Interested In

• TD Cowen Assumes Shattuck Labs (STTK) at Buy
• Polygon Joins Digital Pound Lab as XRP Rallies, Best Altcoin To Buy Now AlphaPepe Builds Toward Launch
• The Apex Institute Reveals What Hiring Managers Actually Want in Cloud and AI Infrastructure Roles